The litigation against manufacturers of pelvic mesh devices continues to increase nationwide. A pelvic mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago, and can serve as an alternative to a hysterectomy. Thousands of women, who were
Bard Agrees to Settle 500 Pelvic Mesh Cases
The litigation against manufacturers of pelvic mesh devices continues to increase nationwide. A pelvic mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago, and can serve as an alternative to a hysterectomy. Thousands of women, who were
Endo International Settles Pelvic Mesh Cases for $830 Million
Endo International Plc (“Endo”) has agreed to pay $830 million to resolve legal claims from women who allege that they were injured by the company’s transvaginal mesh devices. Endo said the settlement will cover a “substantial majority” of the mesh litigation brought against its American Medical Systems subsidiary. This settlement comes only one
FDA Announces New Safety Assessment for Pradaxa
The dangers associated with Pradaxa use are well known. Since reaching the United States’ market in 2010, Pradaxa has been linked to hundreds of deaths. The Food and Drug Administration (FDA) has received numerous adverse event reports for injuries and complications from Pradaxa use.
Physicians and analysts have commented that the health risks associated with
Parties Preparing Consolidated Pleadings in Byetta, Januvia/Janumet and Victoza Litigation
As we have previously reported, the United States Judicial Panel on Multidistrict Litigation (JPML) granted multidistrict litigation (MDL) treatment to the incretin mimetic litigation, meaning that all federal lawsuits filed across the United States are now centralized in one judicial district. The incretin mimetic litigation, which includes the medications Byetta, Januvia/Janumet and Victoza, was
Johnson & Johnson Reportedly Agrees to Settle DePuy ASR Lawsuits for $4 Billion
As we have previously reported, DePuy Orthopaedics, Inc. has recalled its ASR hip replacement device. There are thousands of cases pending across the country related to the ASR device. These cases continue to proceed in state and federal courts.
The New York Times reports that DePuy Orthopaedics, Inc., a subsidiary of Johnson & Johnson,
ADA Asks for Incretin Mimetic Data
As we have previously reported, recent evidence suggests that incretin mimetic medications are linked to pancreatitis and pancreatic cancer. The American Diabetes Association (ADA) has asked all pharmaceutical companies involved in the development or marketing of incretin-based medications to make patient level data on their products available for an independent review. The ADA is
DePuy ASR Lawsuits Move Forward in New Jersey
As we have previously reported, DePuy Orthopaedics, Inc. has recalled its ASR hip replacement device. There are thousands of cases pending across the country related to the ASR device. These cases continue to proceed in state and federal courts.
Continue Reading DePuy ASR Lawsuits Move Forward in New Jersey
Vaginal Mesh MDL Consolidated in West Virginia
As we have previously reported, the vaginal mesh implant litigation continues to move forward across the country. A mesh implant is a synthetic material implanted and tied to ligaments or bone to lift and support internal organs. The implants were introduced over a decade ago and serve as an alternative to hysterectomy. Thousands of
Motion to Consolidate Incretin Mimetic Cases into One Multidistrict Litigation Currently Pending
Researchers at Johns Hopkins University have recently determined that a number of incretin mimetic diabetes medications like Byetta, Januvia/Janumet and Victoza could be linked to pancreatitis and pancreatic cancer.
A motion to consolidate the incretin mimetic cases into one MDL is currently pending. The Judicial Panel on Multidistrict Litigation (JPML) will likely hear oral argument,